ArticleCell proliferation2022
Insight into the antibacterial resistance of graphdiyne functionalized by silver nanoparticles.
Article in Cell proliferation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 22 citations in OpenAlex.
- Graphdiyne biomaterials: from characterization to properties and applications.Journal of nanobiotechnology · 2025Review
- Photosensitive Hydrogels Encapsulating DPSCs and AgNPs for Dental Pulp Regeneration.International dental journal · 2024Article
- YTHDF1 mediates N-methyl-N-nitrosourea-induced gastric carcinogenesis by controlling HSPH1 translation.Cell proliferation · 2024Article
- Engineering a pH-responsive polymeric micelle co-loaded with paclitaxel and triptolide for breast cancer therapy.Cell proliferation · 2024Article
- Machine Learning Tools to Assist the Synthesis of Antibacterial Carbon Dots.International journal of nanomedicine · 2024Article
- Insight into the antibacterial resistance of graphdiyne functionalized by silver nanoparticles.Cell proliferation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesSilver nanoparticles (AgNPs) tend to aggregate spontaneously due to larger surface-to-volume ratio, which causes decreased antibacterial activity and even enhanced antimicrobial resistance (AMR). Here, we aim to improve the stability of AgNPs by employing a growth anchor graphdiyne (GDY) to overcome these shortcomings. MATERIALS AND
methodsBacillus subtilis and Escherichia coli were selected to represent gram-positive and gram-negative bacteria, respectively. Transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), scanning electron microscopy (SEM)-EDS mapping and inductively coupled plasma mass spectrometry (ICP-MS) were carried out to characterize the physiochemical properties of materials. The antimicrobial property was determined by turbidimetry and plate colony-counting methods. The physiology of bacteria was detected by SEM and confocal imaging, such as morphology, reactive oxygen species (ROS) and cell membrane.
resultsWe successfully synthesized a hybrid graphdiyne @ silver nanoparticles (GDY@Ag) by an environment-friendly approach without any reductants. The hybrid showed high stability and excellent broad-spectrum antibacterial activity towards both gram-positive and gram-negative bacteria. It killed bacteria through membrane destruction and ROS production. Additionally, GDY@Ag did not induce the development of the bacterial resistance after repeated exposure.
conclusionsGDY@Ag composite combats bacteria by synergetic action of GDY and AgNPs. Especially, GDY@Ag can preserve its bacterial susceptibility after repeated exposure compared to antibiotics. Our findings provide an avenue to design innovative antibacterial agents for effective sterilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.